LAS VEGAS, Aug. 19, 2015 /PRNewswire/ -- DigiPath Labs, the cannabis testing subsidiary of DigiPath, Inc. (OTCQB: DIGP), has cleared the way for the opening of the first cannabis dispensary in Southern Nevada. The state-of-the-art cannabis testing facility performed extensive quality assurance testing on the first batch of cannabis harvested by Alternative Medicine Association and approved it for medical use. The green light from DigiPath Labs should expedite the opening of Euphoria Wellness, which plans to open in Las Vegas soon, and is exciting news for patients who eagerly await access to safe, reliable medicinal cannabis.
"This is a huge milestone for patients in Las Vegas and the rest of Southern Nevada," explains Todd Denkin, DigiPath Labs' CEO. "We have been gearing up for this day for well over a year, and we are staffed and equipped to be able to provide cannabis testing services for not only the region, but the entire state."
The opening of cannabis dispensaries in Nevada was 15 years in the making. Although Nevada began allowing medical marijuana use in 2001, it only permitted attending physicians to recommend the use of cannabis for patients and extended legal protection for patients to grow up to 12 plants and possess up to 2.5 ounces of cannabis in a single 14-day period.
In April 2014, Senate Bill 374 expanded patient access by establishing a statewide medical cannabis distribution program, which allows up to 66 dispensaries and 200 production facilities to operate in the Silver State. The program was designed and is regulated by the Department of Health and Human Services.
Nevada Medical Marijuana Association Executive Director Will Adler was recently quoted by the Las Vegas Sun as stating that the state's strict rules are designed to prevent problems and become "the gold standard for the country." The rules include seed-to-sale tracking systems and testing processes that measure product potency and help screen out products that contain hundreds of potentially harmful contaminants, including pesticides and mold.
"Standards are seamlessly integrated into our lives—and for very good reasons," says Dr. Cindy Orser, DigiPath Labs' Chief Science Officer. "When you take a 350 mg aspirin, you can be confident it won't contain 600 mg or might not contain any aspirin at all. You don't have to worry it might contain mercury, pesticides, or mold. We need that kind of reliability in marijuana products, especially those intended for patients."
Dr. Orser is routinely called upon to deliver expert testimony on cannabis testing, which helps lawmakers and law enforcement understand the importance of cannabis testing and adopting rigorous standards. Dr. Orser recently spoke about the importance of standards in medical cannabis testing at the Conference of Western Attorneys General (CWAG).
For more information about DigiPath Labs, go to http://digipathlabs.com.
About DigiPath, Inc. (OTCQB: DIGP)
DigiPath, Inc., supports the cannabis industry's best practices for reliable testing, education, and training, and brings unbiased cannabis news coverage to the nation. DigiPath's three business units are DigiPath Labs, TNM News Corp., and DigiPath Corp. For more information about DigiPath Labs, go to http://digipath.com.
Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events. Forward-looking statements are based on information available at the time they are made, and are subject to risks and uncertainties that could cause actual performance to differ materially from those stated. For a description of the risk factors and uncertainties affecting DigiPath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements.
SOURCE DigiPath, Inc.